116 related articles for article (PubMed ID: 27766872)
1. Pharmacokinetics and Metabolism of Selective Oxoeicosanoid (OXE) Receptor Antagonists and Their Effects on 5-Oxo-6,8,11,14-eicosatetraenoic Acid (5-Oxo-ETE)-Induced Granulocyte Activation in Monkeys.
Cossette C; Chourey S; Ye Q; Nagendra Reddy C; Gore V; Gravel S; Slobodchikova I; Vuckovic D; Rokach J; Powell WS
J Med Chem; 2016 Nov; 59(22):10127-10146. PubMed ID: 27766872
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and pharmacokinetics of a potent N-acylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) in rats and monkeys.
Reddy CN; Alhamza H; Chourey S; Ye Q; Gore V; Cossette C; Gravel S; Slobodchikova I; Vuckovic D; Rokach J; Powell WS
Eur J Pharm Sci; 2018 Mar; 115():88-99. PubMed ID: 29339225
[TBL] [Abstract][Full Text] [Related]
3. In vivo α-hydroxylation of a 2-alkylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid in monkeys.
Chourey S; Ye Q; Reddy CN; Cossette C; Gravel S; Zeller M; Slobodchikova I; Vuckovic D; Rokach J; Powell WS
Biochem Pharmacol; 2017 Aug; 138():107-118. PubMed ID: 28476332
[TBL] [Abstract][Full Text] [Related]
4. Novel Highly Potent and Metabolically Resistant Oxoeicosanoid (OXE) Receptor Antagonists That Block the Actions of the Granulocyte Chemoattractant 5-Oxo-6,8,11,14-Eicosatetraenoic Acid (5-oxo-ETE).
Chourey S; Ye Q; Reddy CN; Wang R; Cossette C; Gravel S; Slobodchikova I; Vuckovic D; Rokach J; Powell WS
J Med Chem; 2018 Jul; 61(14):5934-5948. PubMed ID: 29972644
[TBL] [Abstract][Full Text] [Related]
5. Targeting the OXE receptor as a potential novel therapy for asthma.
Powell WS; Rokach J
Biochem Pharmacol; 2020 Sep; 179():113930. PubMed ID: 32240653
[TBL] [Abstract][Full Text] [Related]
6. The eosinophil chemoattractant 5-oxo-ETE and the OXE receptor.
Powell WS; Rokach J
Prog Lipid Res; 2013 Oct; 52(4):651-65. PubMed ID: 24056189
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of allergen-induced dermal eosinophilia by an oxoeicosanoid receptor antagonist in non-human primates.
Miller LA; Cossette C; Chourey S; Ye Q; Reddy CN; Rokach J; Powell WS
Br J Pharmacol; 2020 Jan; 177(2):360-371. PubMed ID: 31655023
[TBL] [Abstract][Full Text] [Related]
8. Biosynthesis and actions of 5-oxoeicosatetraenoic acid (5-oxo-ETE) on feline granulocytes.
Cossette C; Gravel S; Reddy CN; Gore V; Chourey S; Ye Q; Snyder NW; Mesaros CA; Blair IA; Lavoie JP; Reinero CR; Rokach J; Powell WS
Biochem Pharmacol; 2015 Aug; 96(3):247-55. PubMed ID: 26032638
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of 5-oxo-6,8,11,14-eicosatetraenoic acid-induced activation of neutrophils and eosinophils by novel indole OXE receptor antagonists.
Gore V; Gravel S; Cossette C; Patel P; Chourey S; Ye Q; Rokach J; Powell WS
J Med Chem; 2014 Jan; 57(2):364-77. PubMed ID: 24351031
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship study of β-oxidation resistant indole-based 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) receptor antagonists.
Ye Q; Chourey S; Wang R; Chintam NR; Gravel S; Powell WS; Rokach J
Bioorg Med Chem Lett; 2017 Oct; 27(20):4770-4776. PubMed ID: 28943042
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of anti-inflammatory OXE (oxoeicosanoid) receptor antagonists by nonhuman primates.
Cossette C; Chourey S; Ye Q; Reddy CN; Wang R; Poulet S; Slobodchikova I; Vuckovic D; Rokach J; Powell WS
Eur J Pharm Sci; 2022 May; 172():106144. PubMed ID: 35158054
[TBL] [Abstract][Full Text] [Related]
12. Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys.
Ye Q; Chourey S; Reddy CN; Wang R; Cossette C; Gravel S; Slobodchikova I; Vuckovic D; Rokach J; Powell WS
Br J Pharmacol; 2020 Jan; 177(2):388-401. PubMed ID: 31655025
[TBL] [Abstract][Full Text] [Related]
13. Structural requirements for activation of the 5-oxo-6E,8Z, 11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity.
Patel P; Cossette C; Anumolu JR; Gravel S; Lesimple A; Mamer OA; Rokach J; Powell WS
J Pharmacol Exp Ther; 2008 May; 325(2):698-707. PubMed ID: 18292294
[TBL] [Abstract][Full Text] [Related]
14. Oxoeicosanoid receptor inhibition alleviates acute myocardial infarction through activation of BCAT1.
Lai Q; Yuan G; Shen L; Zhang L; Fu F; Liu Z; Zhang Y; Kou J; Liu S; Yu B; Li F
Basic Res Cardiol; 2021 Jan; 116(1):3. PubMed ID: 33484341
[TBL] [Abstract][Full Text] [Related]
15. A biased non-Gαi OXE-R antagonist demonstrates that Gαi protein subunit is not directly involved in neutrophil, eosinophil, and monocyte activation by 5-oxo-ETE.
Konya V; Blättermann S; Jandl K; Platzer W; Ottersbach PA; Marsche G; Gütschow M; Kostenis E; Heinemann A
J Immunol; 2014 May; 192(10):4774-82. PubMed ID: 24733850
[TBL] [Abstract][Full Text] [Related]
16. 5-Lipoxygenase products regulate basophil functions: 5-Oxo-ETE elicits migration, and leukotriene B(4) induces degranulation.
Iikura M; Suzukawa M; Yamaguchi M; Sekiya T; Komiya A; Yoshimura-Uchiyama C; Nagase H; Matsushima K; Yamamoto K; Hirai K
J Allergy Clin Immunol; 2005 Sep; 116(3):578-85. PubMed ID: 16159627
[TBL] [Abstract][Full Text] [Related]
17. Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid.
Powell WS; Rokach J
Biochim Biophys Acta; 2015 Apr; 1851(4):340-55. PubMed ID: 25449650
[TBL] [Abstract][Full Text] [Related]
18. Concise Syntheses of Microsomal Metabolites of a Potent OXE (Oxoeicosanoid) Receptor Antagonist.
Chourey S; Wang R; Ye Q; Reddy CN; Sun S; Takenaka N; Powell WS; Rokach J
Chem Pharm Bull (Tokyo); 2023; 71(7):534-544. PubMed ID: 37394602
[TBL] [Abstract][Full Text] [Related]
19. 5-Oxo-ETE and the OXE receptor.
Grant GE; Rokach J; Powell WS
Prostaglandins Other Lipid Mediat; 2009 Sep; 89(3-4):98-104. PubMed ID: 19450703
[TBL] [Abstract][Full Text] [Related]
20. 5-oxo-ETE activates migration of H295R adrenocortical cells via MAPK and PKC pathways.
Neuman I; Cooke M; Lemiña NA; Kazanietz MG; Cornejo Maciel F
Prostaglandins Other Lipid Mediat; 2019 Oct; 144():106346. PubMed ID: 31301403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]